bioAffinity Technologies ... (BIAF)
bioAffinity Statistics
Share Statistics
bioAffinity has 15.58M shares outstanding. The number of shares has increased by 36.12% in one year.
| Shares Outstanding | 15.58M |
| Shares Change (YoY) | 36.12% |
| Shares Change (QoQ) | 15.52% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.42M |
| Failed to Deliver (FTD) Shares | 5.19K |
| FTD / Avg. Volume | 2.01% |
Short Selling Information
The latest short interest is 271.43K, so 1.74% of the outstanding shares have been sold short.
| Short Interest | 271.43K |
| Short % of Shares Out | 1.74% |
| Short % of Float | 2.88% |
| Short Ratio (days to cover) | 1.43 |
Valuation Ratios
The PE ratio is -1.62 and the forward PE ratio is -1.2. bioAffinity's PEG ratio is 0.03.
| PE Ratio | -1.62 |
| Forward PE | -1.2 |
| PS Ratio | 5.08 |
| Forward PS | 0.3 |
| PB Ratio | 2.65 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | 0.03 |
Enterprise Valuation
bioAffinity Technologies Inc. has an Enterprise Value (EV) of 11.62M.
| EV / Earnings | -1.46 |
| EV / Sales | 4.59 |
| EV / EBITDA | -1.52 |
| EV / EBIT | -1.46 |
| EV / FCF | -1.92 |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.77 |
| Quick Ratio | 1.76 |
| Debt / Equity | 0.33 |
| Total Debt / Capitalization | 24.54 |
| Cash Flow / Debt | -3.82 |
| Interest Coverage | -214.77 |
Financial Efficiency
Return on equity (ROE) is -1.63% and return on capital (ROIC) is -124.25%.
| Return on Equity (ROE) | -1.63% |
| Return on Assets (ROA) | -0.97% |
| Return on Capital (ROIC) | -124.25% |
| Revenue Per Employee | $33,766.65 |
| Profits Per Employee | $-105,826.81 |
| Employee Count | 75 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 94.18 |
Taxes
| Income Tax | 20.99K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.85% in the last 52 weeks. The beta is 3.14, so bioAffinity's price volatility has been higher than the market average.
| Beta | 3.14 |
| 52-Week Price Change | -86.85% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 26.41 |
| Average Volume (20 Days) | 259K |
Income Statement
In the last 12 months, bioAffinity had revenue of 2.53M and earned -7.94M in profits. Earnings per share was -0.91.
| Revenue | 2.53M |
| Gross Profit | 791.62K |
| Operating Income | -7.97M |
| Net Income | -7.94M |
| EBITDA | -7.63M |
| EBIT | -7.97M |
| Earnings Per Share (EPS) | -0.91 |
Balance Sheet
The company has 2.82M in cash and 1.58M in debt, giving a net cash position of 1.24M.
| Cash & Cash Equivalents | 2.82M |
| Total Debt | 1.58M |
| Net Cash | 1.24M |
| Retained Earnings | -44.6M |
| Total Assets | 6.55M |
| Working Capital | 57.97K |
Cash Flow
In the last 12 months, operating cash flow was -6.04M and capital expenditures -22.9K, giving a free cash flow of -6.06M.
| Operating Cash Flow | -6.04M |
| Capital Expenditures | -22.9K |
| Free Cash Flow | -6.06M |
| FCF Per Share | -0.69 |
Margins
Gross margin is 31.26%, with operating and profit margins of -314.84% and -313.41%.
| Gross Margin | 31.26% |
| Operating Margin | -314.84% |
| Pretax Margin | -312.58% |
| Profit Margin | -313.41% |
| EBITDA Margin | -301.26% |
| EBIT Margin | -314.84% |
| FCF Margin | -239.32% |
Dividends & Yields
BIAF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -325% |
| FCF Yield | -140.49% |
Analyst Forecast
The average price target for BIAF is $6, which is 2042.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 2042.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -12.82 |
| Piotroski F-Score | 2 |